Last reviewed · How we verify
R-GemOx
R-GemOx is a combination of gemcitabine and oxaliplatin, used to treat various cancers.
R-GemOx is a combination of gemcitabine and oxaliplatin, used to treat various cancers. Used for Advanced pancreatic cancer, Advanced biliary tract cancer.
At a glance
| Generic name | R-GemOx |
|---|---|
| Also known as | Rituximab Injection, Gemcitabine Hydrochloride for Injection, Oxaliplatin Injection, Rituximab, Gemcitabine |
| Sponsor | Hutchmed |
| Drug class | chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
R-GemOx is a chemotherapy drug that works by interfering with the growth of cancer cells, ultimately leading to cell death. It is a combination of two chemotherapy agents, gemcitabine and oxaliplatin, which have different mechanisms of action but work together to enhance the treatment's effectiveness.
Approved indications
- Advanced pancreatic cancer
- Advanced biliary tract cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
Key clinical trials
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PHASE3)
- Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (PHASE3)
- A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (PHASE3)
- Low Dose Epcoritamab Plus GemOx in R/R DLBCL (PHASE2)
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (PHASE1, PHASE2)
- A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PHASE3)
- Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R-GemOx CI brief — competitive landscape report
- R-GemOx updates RSS · CI watch RSS
- Hutchmed portfolio CI